201 related articles for article (PubMed ID: 36780766)
1. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib.
Miao E; Eichholz JE; Lebow ES; Flynn J; Zhang Z; Walch H; Hubbeling H; Beal K; Moss NS; Yu KK; Meng A; Kelly DW; Gomez DR; Li BT; Rimner A; Schultz N; Drilon A; Imber BS; Pike LRG
Lung Cancer; 2023 Apr; 178():57-65. PubMed ID: 36780766
[TBL] [Abstract][Full Text] [Related]
2. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
Zou Z; Xing P; Hao X; Wang Y; Song X; Shan L; Zhang C; Liu Z; Ma K; Dong G; Li J
BMC Med; 2022 Jan; 20(1):12. PubMed ID: 35039026
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
4. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
6. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
Langston J; Patil T; Ross Camidge D; Bunn PA; Schenk EL; Pacheco JM; Jurica J; Waxweiler TV; Kavanagh BD; Rusthoven CG
Lung Cancer; 2023 Apr; 178():103-107. PubMed ID: 36809719
[TBL] [Abstract][Full Text] [Related]
7. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.
Thomas NJ; Myall NJ; Sun F; Patil T; Mushtaq R; Yu C; Sinha S; Pollom EL; Nagpal S; Camidge DR; Rusthoven CG; Braunstein SE; Wakelee HA; McCoach CE
J Thorac Oncol; 2022 Jan; 17(1):116-129. PubMed ID: 34455066
[TBL] [Abstract][Full Text] [Related]
8. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
9. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.
Li N; Xie M; Zhou Z; Sheng J; Yu X; Fan Y
Thorac Cancer; 2023 Jan; 14(3):237-245. PubMed ID: 36411716
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
13. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
[TBL] [Abstract][Full Text] [Related]
14. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
[TBL] [Abstract][Full Text] [Related]
16. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences.
Cicin I; Martin C; Haddad CK; Kim SW; Smolin A; Abdillah A; Yang X
Crit Rev Oncol Hematol; 2022 Dec; 180():103847. PubMed ID: 36257531
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
18. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
19. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
